Should You Buy NuScale While It's Below $15?

NuScale Power remains pre-commercial with about $900 million in cash, but 2025 revenue was only $31.5 million while net losses widened to $355.8 million, and first-quarter 2026 revenue fell to nearly nothing. The stock is down more than 26% this year, has a beta above 2, and is facing a class action lawsuit over alleged misstatements about ENTRA1. Offsetting risks are NRC approval for its SMR design and pipeline projects with TVA/ENTRA1 and RoPower that could drive revenue in the early 2030s.

Analysis

SMR remains a classic “option on eventual commercialization,” but the market is increasingly pricing in that the option is drifting farther out-the-money. The first-order issue is not technology risk anymore; it is financing efficiency: every quarter of delay converts cash runway into a slower-burn liquidation of equity value, and that asymmetry gets worse when a stock already trades with >2 beta. In this setup, the shares can stay bid on headline catalysts, but the expected path is still downward unless execution converts into signed, financeable project milestones.

The more important second-order dynamic is competitive gating. NRC approval is a real barrier, but it may become less valuable if buyers care more about deliverability, fuel access, and balance-sheet credibility than design certification alone. That creates a path for OKLO and other peers to compete on ecosystem partnerships and supply-chain readiness, even if they lag on formal approval. In other words, the winner may be the company that de-risks procurement and project finance fastest, not necessarily the one that won the regulatory race.

The litigation overhang is especially problematic because it attacks the equity story’s multiple more than the near-term P&L. Even if damages are manageable, discovery risk can suppress institutional sponsorship and keep borrow elevated, which supports continued volatility. The bullish counterargument is that a 2-3 year delay is already embedded in the narrative; if management can show one credible FID or utility-backed milestone, the stock could re-rate sharply because the market is paying for survival, not current earnings.

Consensus may be underestimating how much of the cash balance is effectively reserved for legal and commercialization optionality rather than free reinvestment. That means the ‘no dilution’ argument is weaker than it looks if project timelines slip again. The better contrarian trade is not to short the name outright, but to express skepticism through relative-value or options structures that monetize time decay and event risk.

Key Decisions for Investors

• Short SMR into strength or buy put spreads 3-6 months out; thesis is multiple compression as commercialization slips and litigation drags, with better-than-1:2 risk/reward if the stock re-tests prior support on no-new-news periods.
• Pair trade: long OKLO / short SMR for 1-2 quarters; if the market continues to reward ecosystem execution and supply-chain visibility over certification alone, SMR underperforms on relative catalysts.
• Avoid outright long exposure in SMR unless there is a confirmed project-finance milestone; the stock remains a high-beta funding story, and waiting for de-risking improves odds of paying for execution rather than hope.
• For existing holders, consider covered calls into spikes in implied volatility; the name’s event-driven swings make premium collection attractive while litigation and commercialization uncertainty cap near-term upside.
• Set a catalyst trigger rather than a price target: only add on evidence of signed, financeable customer commitments or legal resolution, because those are the two events most likely to compress the risk premium.